Piper Sandler Companies (PIPR)
Bid | 320 |
Market Cap | 5.86B |
Revenue (ttm) | 1.58B |
Net Income (ttm) | 210.94M |
EPS (ttm) | 11.86 |
PE Ratio (ttm) | 27.95 |
Forward PE | 17.82 |
Analyst | Hold |
Ask | 332.02 |
Volume | 70,843 |
Avg. Volume (20D) | 155,674 |
Open | 325.58 |
Previous Close | 322.37 |
Day's Range | 324.76 - 331.91 |
52-Week Range | 202.91 - 351.80 |
Beta | 1.49 |
About PIPR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for PIPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

20 hours ago · https://thefly.com
Dollar Tree price target lowered to $108 from $112 at Piper SandlerPiper Sandler analyst Peter Keith lowered the firm's price target on Dollar Tree to $108 from $112 and keeps a Neutral rating on the shares following Q2 earnings. Q2 was solid with a 6.5% comp that wa...

20 hours ago · https://thefly.com
Salesforce price target lowered to $315 from $335 at Piper SandlerPiper Sandler lowered the firm's price target on Salesforce to $315 from $335 and keeps an Overweight rating on the shares. Investor sentiment on Salesforce remained bearish going into the July-ending...

2 weeks ago · https://thefly.com
Ollie's Bargain Outlet price target raised to $150 from $123 at Piper SandlerPiper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as ...

2 weeks ago · https://thefly.com
Dollar Tree price target raised to $112 from $93 at Piper SandlerPiper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved...

2 weeks ago · https://thefly.com
Piper starts Summit Therapeutics with Neutral on high expectationsPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi...

2 weeks ago · https://thefly.com
Ormat Technologies price target raised to $90 from $78 at Piper SandlerPiper Sandler raised the firm's price target on Ormat Technologies to $90 from $78 and keeps a Neutral rating on the shares. Shares are up 33% year to date as the improving regulatory environment and ...

2 weeks ago · https://thefly.com
Piper starts Janux Therapeutics with an Overweight on 'best-in-class' potentialAs previously reported, Piper Sandler initiated coverage of Janux Therapeutics with an Overweight rating and $42 price target. While noting that investor sentiment has waned over the course of 2025 fo...